Torqur

TORL

TORL BioTherapeutics develops antibody-based immunotherapies and drug conjugates to treat patients with various solid tumours and haematological cancers.

Endeavor BioMedicines

This clinical-stage biotechnology company develops small-molecule inhibitors and therapies for patients with oncology and fibrotic lung diseases.

TORL BioTherapeutics

This biopharmaceutical company develops antibody-drug conjugates and monoclonal antibodies to treat various cancers for patients with unmet medical needs.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.

TargeGen

This company develops small molecule kinase inhibitors to treat blood disorders and inflammatory diseases for patients with unmet medical needs.

DermBiont

This clinical-stage biotechnology company develops targeted topical therapeutics to treat skin diseases, such as hyperpigmentation and seborrheic keratoses, for patients with dermatological conditions.

Fore Biotherapeutics

This precision oncology company develops targeted therapies for patients with unaddressed cancer mutations, including a specific BRAF inhibitor for advanced solid tumours.

D3 Bio

This biotechnology company develops precision medicines and oncology therapeutics for patients with cancer and immunological conditions.